Literature DB >> 33466414

Identification of Targets from LRRK2 Rescue Phenotypes.

Joanne Toh1, Ling Ling Chua1, Patrick Ho1, Edwin Sandanaraj1,2, Carol Tang3,4,5, Hongyan Wang6,7,8, Eng King Tan9,10.   

Abstract

Parkinson's disease (PD) is an age-dependent neurodegenerative condition. Leucine-rich repeat kinase 2 (LRRK2) mutations are the most frequent cause of sporadic and autosomal dominant PD. The exact role of LRRK2 protective variants (R1398H, N551K) together with a pathogenic mutant (G2019S) in aging and neurodegeneration is unknown. We generated the following myc-tagged UAS-LRRK2 transgenic Drosophila: LRRK2 (WT), N551K, R1398H, G2019S single allele, and double-mutants (N551K/G2019S or R1398H/G2019S). The protective variants alone were able to suppress the phenotypic effects caused by the pathogenic LRRK2 mutation. Next, we conducted RNA-sequencing using mRNA isolated from dopaminergic neurons of these different groups of transgenic Drosophila. Using pathway enrichment analysis, we identified the top 10 modules (p < 0.05), with "LRRK2 in neurons in Parkinson's disease" among the candidates. Further dissection of this pathway identified the most significantly modulated gene nodes such as eEF1A2, ACTB, eEF1A, and actin cytoskeleton reorganization. The induction of the pathway was successfully restored by the R1398H protective variant and R1398H-G2019S or N551K-G2019S rescue experiments. The oxidoreductase family of genes was also active in the pathogenic mutant and restored in protective and rescue variants. In summary, we provide in vivo evidence supporting the neuroprotective effects of LRRK2 variants. RNA sequencing of dopaminergic neurons identified upregulation of specific gene pathways in the Drosophila carrying the pathogenic variant, and this was restored in the rescue phenotypes. Using protective gene variants, our study identifies potential new targets and provides proof of principle of a new therapeutic approach that will further our understanding of aging and neurodegeneration in PD.

Entities:  

Keywords:  Drosophila melanogaster; LRRK2; Parkinson’s disease; RNA sequencing; neurodegeneration

Year:  2021        PMID: 33466414      PMCID: PMC7824855          DOI: 10.3390/cells10010076

Source DB:  PubMed          Journal:  Cells        ISSN: 2073-4409            Impact factor:   6.600


  64 in total

1.  Microarray expression analysis in idiopathic and LRRK2-associated Parkinson's disease.

Authors:  Teresa Botta-Orfila; Eduard Tolosa; Ellen Gelpi; Alex Sànchez-Pla; Maria-José Martí; Francesc Valldeoriola; Manel Fernández; Francesc Carmona; Mario Ezquerra
Journal:  Neurobiol Dis       Date:  2011-09-16       Impact factor: 5.996

Review 2.  Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2).

Authors:  Ryan D Mills; Terrence D Mulhern; Fei Liu; Janetta G Culvenor; Heung-Chin Cheng
Journal:  Hum Mutat       Date:  2014-02-24       Impact factor: 4.878

3.  alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

Authors:  M G Spillantini; R A Crowther; R Jakes; M Hasegawa; M Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Transcriptome analysis of LRRK2 knock-out microglia cells reveals alterations of inflammatory- and oxidative stress-related pathways upon treatment with α-synuclein fibrils.

Authors:  Isabella Russo; Alice Kaganovich; Jinhui Ding; Natalie Landeck; Adamantios Mamais; Tatiana Varanita; Alice Biosa; Isabella Tessari; Luigi Bubacco; Elisa Greggio; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2019-05-15       Impact factor: 5.996

Review 5.  LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.

Authors:  Yulan Xiong; Valina L Dawson; Ted M Dawson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

6.  Phosphorylation of ezrin/radixin/moesin proteins by LRRK2 promotes the rearrangement of actin cytoskeleton in neuronal morphogenesis.

Authors:  Loukia Parisiadou; Chengsong Xie; Hyun Jin Cho; Xian Lin; Xing-Long Gu; Cai-Xia Long; Evy Lobbestael; Veerle Baekelandt; Jean-Marc Taymans; Lixin Sun; Huaibin Cai
Journal:  J Neurosci       Date:  2009-11-04       Impact factor: 6.167

7.  Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians.

Authors:  Eng-King Tan; Yi Zhao; Louis Tan; Hui-Qin Lim; Jasinda Lee; Yih Yuen; Ratnagopal Pavanni; Meng-Cheong Wong; Stephanie Fook-Chong; Jian-Jun Liu
Journal:  Mov Disord       Date:  2007-09-15       Impact factor: 10.338

8.  Sequences located within the N-terminus of the PD-linked LRRK2 lead to increased aggregation and attenuation of 6-hydroxydopamine-induced cell death.

Authors:  Neeraj Pandey; Mark T Fahey; Yuh-Jiin I Jong; Karen L O'Malley
Journal:  PLoS One       Date:  2012-09-13       Impact factor: 3.240

9.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity.

Authors:  Mahaboobi Jaleel; R Jeremy Nichols; Maria Deak; David G Campbell; Frank Gillardon; Axel Knebel; Dario R Alessi
Journal:  Biochem J       Date:  2007-07-15       Impact factor: 3.857

10.  Protective LRRK2 R1398H Variant Enhances GTPase and Wnt Signaling Activity.

Authors:  Jonathon Nixon-Abell; Daniel C Berwick; Simone Grannó; Victoria A Spain; Craig Blackstone; Kirsten Harvey
Journal:  Front Mol Neurosci       Date:  2016-03-08       Impact factor: 5.639

View more
  2 in total

1.  Coding and Noncoding Variation in LRRK2 and Parkinson's Disease Risk.

Authors:  Julie Lake; Xylena Reed; Rebekah G Langston; Mike A Nalls; Ziv Gan-Or; Mark R Cookson; Andrew B Singleton; Cornelis Blauwendraat; Hampton L Leonard
Journal:  Mov Disord       Date:  2021-09-20       Impact factor: 9.698

2.  Functional Analyses of Two Novel LRRK2 Pathogenic Variants in Familial Parkinson's Disease.

Authors:  Marie-Christine Chartier-Harlin; Jean-Marc Taymans; Ilda Coku; Eugénie Mutez; Sabiha Eddarkaoui; Sébastien Carrier; Antoine Marchand; Claire Deldycke; Liesel Goveas; Guillaume Baille; Mélissa Tir; Romain Magnez; Xavier Thuru; Gaëlle Vermeersch; Wim Vandenberghe; Luc Buée; Luc Defebvre; Bernard Sablonnière; Vincent Huin
Journal:  Mov Disord       Date:  2022-06-16       Impact factor: 9.698

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.